Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes

Reference

• BAEK, M. S., KIM, J. Y., MYUNG, S. W., YIM, Y. H., JEONG, J. H. and Km, D. H., 2001, Metabolism of dimethy1-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybipheny1-2,2'-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome CYP isoforms involved. Drug Metabolism and Disposition, 29, 381–388.
   PubMed Web of Science ®Google Scholar
• Booms, A. R., 1995, Prediction of inhibitory drug—drug interactions by studies in vitro. In G. M. Pacifici and G. N. Gracchia (eds), Advances in Drug Metabolism in Man (Luxembourg: European Commission), pp. 513–539.
   Google Scholar
• BRADFORD, M. M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein—dye binding. Analytical Biochemistry, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• BROCKS, D. R., UPWARD, J. W., GEORGIOU, P., STELMAN, G., DOYLE, E., ALLEN, E., WYLD, P. and DENNIS, M. J., 1996, The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. European Journal of Clinical Pharmacology, 51, 303–308.
   PubMed Web of Science ®Google Scholar
• BROLY, F., LIBERSA, C. L., LHERMITTE, M., BECHTEL, P. and DUPUIS, B., 1989, Effect of quinidine on the dextromethorphan 0-demethylase activity of microsomal fractions from human liver. British Journal of Clinical Pharmacology, 28, 29–36.
   PubMed Web of Science ®Google Scholar
• CHIBA, M., XU, X., NISHIME, J. A., BALANI, S. K. and LIN, J. H., 1997, Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metabolism and Disposition, 25, 1022–1031.
   PubMed Web of Science ®Google Scholar
• COURT, M. H., VON MOLTKE, L. L., SHADER, R. I. and GREENBLATT, D. J., 1997, Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharmaceutics and Drug Disposition, 18, 213–226.
   PubMed Web of Science ®Google Scholar
• DEMPSEY, 0. J., 2000, Leukotriene receptor antagonist therapy. Postgraduate Medical Journal, 76, 767–773.
   Google Scholar
• DOLLERY, C., 1999, Therapeutic Drugs (Edinburgh: Churchill Livingstone).
   Google Scholar
• DRAZEN, J. M., ISRAEL, E. and O'BYRNE, P. M., 1999, Treatment of asthma with drugs modifying the leukotriene pathway. New England Journal of Medicine, 340, 197–206.
   Google Scholar
• DUNN, C. J. and GOA, K. L., 2001, Zafirlukast, an update of its pharmacology and therapeutic efficacy in asthma. Drugs, 61, 285–315.
   PubMed Web of Science ®Google Scholar
• FUJIMURA, M., SAKAHOTO, S., KAMIS, Y. and MATSUDA, T., 1993, Effect of a leukotriene antagonist ONO 1078 on bronchial hyper-responsiveness in patients with asthma. Respiratory Medicine, 87, 133–138.
   PubMed Web of Science ®Google Scholar
• GALETIN, A., CLARKE, S. E. and HOUSTON, J. B., 2002, Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metabolism and Disposition, 30, 1512–1522.
   PubMed Web of Science ®Google Scholar
• GAREY, K. W., PELoouThr, C. A., GODO, P. G., NAFZIGER, A. N. and AMSDEN, G. W., 1999, Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrobial Agents and Chemotherapy, 43, 1152–1155.
   PubMedGoogle Scholar
• KATIAL, R. K., STELZLE, R. C., BONNER, M. W., MARINO, M., CANTILENA, L. R. and SMITH, L. J., 1998, A drug interaction between zafirlukast and theophylline. Archives of International Medicine, 158, 1713–1715.
   PubMed Web of Science ®Google Scholar
• KIM, J. Y., BAEK, M., LEE, S., KIM, S. 0., DONG, M. S., KIM, B. R. and KIM, D. H., 2001, Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethy1-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybipheny1-2,2'-dicarboxylate. Drug Metabolism and Disposition, 29, 1555–1560.
   Google Scholar
• KNORR, B., HOLLAND, S., ROGERS, J. D., NGUYEN, H. H. and REISS, T. F., 2000, Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose subjections. Journal of Allergy and Clinical Immunology, 106, S171—S178.
   Google Scholar
• Ko, J. W., SUKHOVA, N., THACKER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   PubMed Web of Science ®Google Scholar
• LUDWIG, E., SCHMID, J., BESCHKE, K. and EBNER, T., 1999, Activation of human cytochrome P-450 3A4-catalysed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. Journal of Pharmacology and Experimental Therapeutics, 290, 1–8.
   PubMed Web of Science ®Google Scholar
• MACHINIST, J. M., MAYER, M. D., SHET, M. S., FERRERO, J. L. and RODRIGUES, A. D., 1995, Identification of the human live cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its dehyroxylated metabolite, Abbott-66193. Drug Metabolism and Disposition, 23, 1163–1174.
   PubMed Web of Science ®Google Scholar
• MCMILLAN, R. M., 2001, Leukotrienes in respiratory disease. Paediatric Respiratory Reviews, 2, 238–244.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• REINUS, J. F., PERSKY, S., BURKIEWICZ, J. S., QUAN, D., BASS, N. M. and DAVERN, T. J., 2000, Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Annals of Internal Medicine, 133, 964–968.
   PubMedGoogle Scholar
• RELLING, M. V., AOYAMA, T., GONZALEZ, F. J. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. Journal of Pharmacology and Experimental Therapeutics, 252, 442–447.
   PubMed Web of Science ®Google Scholar
• SAMUELSSON, B., 1983, Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 220, 568–575.
   PubMed Web of Science ®Google Scholar
• SEGEL, I. H., 1975, Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (New York: Wiley).
   Google Scholar
• SHADER, R. I., GRANDA, B. W., VON MOLTKE, L. L., GIANCARLO, G. M. and GREENBLATT, D. J., 1999, Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharmaceutics and Drug Disposition, 20, 385–388.
   PubMed Web of Science ®Google Scholar
• SHIN, J. G., KANE, K. and FLOCKHART, D. A., 2001, Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. British Journal of Clinical Pharmacology, 51,45–52.
   PubMed Web of Science ®Google Scholar
• SHIN, J. G., SOUKHOVA, N. and FLOCKHART, D. A., 1999, Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metabolism and Disposition, 27, 1078–1084.
   PubMed Web of Science ®Google Scholar
• SHON, J. H., YOON, Y. R., KIM, K. A., Lim, Y. C., LEE, K. J., PARK, J. Y., CHA, I. J., FLOCKHART, D. A. and SHIN, J. G., 2002, Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics, 12, 111–119.
   PubMedGoogle Scholar
• SUTTLE, A. B., VARGO, D. L., WILKINSON, L. A., BIRMINGHAM, B. K. and LASSETER, K., 1997, Effect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men. Clinical Pharmacology and Therapeutics, 61, 186.
   Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., McMANus, M. E., TURKEY, R. H., QUATTROCHT, L. C., GELBOIN, H. V. and MINERS, J. 0., 1993, Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   Google Scholar
• TESTINO, JR, S. A. and PATONAY, G., 2003, High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 30, 1459–1467.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., HARTWELL, P. S., RAISYS, V. A., MARSH, C. L., McVicAE, J. P., BARR, D. M., PERKINS, J. D. and CARTERS, R. L., 1994, Use of midazolam as a human cytochrome P450 3A probe: I. In vitro—in vivo correla-tions in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549–556.
   PubMed Web of Science ®Google Scholar
• VARGO, D. L., YEH, C., LASSETER, K., SHAMBIEN, E. C. and BIRMINGHAM, B. K., 1997, Effect of zafirlukast on prothrombin time and area under the curve of warfarin. Journal of Clinical Pharmacology, 37, 870.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., COTREAU-BIBBO, M. M., PRITCHARD, G. A., WRIGHT, C. E. and SHADER, R. I., 1996, Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370–379.
   Google Scholar
• WENZEL, S. E., 1998, New approaches to anti-inflammatory therapy for asthma, American Journal of Medicine, 104, 287–300.
   Google Scholar
• WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VAN DEN BRADEN, M., 1993, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240–245.
   Google Scholar